A platelet derived growth factor delivery system for bone regeneration.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 22576317)

Published in J Mater Sci Mater Med on May 11, 2012

Authors

J J Delgado1, Esther Sánchez, Manuel Baro, Ricardo Reyes, Carmen Evora, Araceli Delgado

Author Affiliations

1: Department of Chemical Engineering and Pharmaceutical Technology, University of La Laguna, La Laguna, Spain.

Articles cited by this

Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89

Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest (2005) 2.80

Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface (2010) 2.69

Current concepts of molecular aspects of bone healing. Injury (2005) 2.56

Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater (2008) 2.54

Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res (2007) 1.77

Polymeric growth factor delivery strategies for tissue engineering. Pharm Res (2003) 1.74

Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am (2008) 1.66

Note on a Method of Determining the Distribution of Pore Sizes in a Porous Material. Proc Natl Acad Sci U S A (1921) 1.45

Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone (1994) 1.31

Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation (2006) 1.19

Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration. J Control Release (2000) 1.11

Enhanced bone formation by controlled growth factor delivery from chitosan-based biomaterials. J Control Release (2002) 1.11

Accelerated fracture healing in the geriatric, osteoporotic rat with recombinant human platelet-derived growth factor-BB and an injectable beta-tricalcium phosphate/collagen matrix. J Orthop Res (2008) 1.10

Expression of platelet-derived growth factor-beta receptors on human fibroblasts. Regulation by recombinant platelet-derived growth factor-BB, IL-1, and tumor necrosis factor-alpha. J Immunol (1992) 1.08

In vitro-in vivo characterization of gentamicin bone implants. J Control Release (2002) 1.02

Adsorption and release of insulin-like growth factor-I on porous tricalcium phosphate implant. J Biomed Mater Res (2000) 1.00

Nanofibrous scaffolds incorporating PDGF-BB microspheres induce chemokine expression and tissue neogenesis in vivo. PLoS One (2008) 0.98

Recombinant human platelet-derived growth factor-BB augmentation of new-bone formation in a rat model of distraction osteogenesis. J Bone Joint Surg Am (2009) 0.93

Local controlled release of VEGF and PDGF from a combined brushite-chitosan system enhances bone regeneration. J Control Release (2009) 0.92

The bone regenerative effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate sponge carrier. J Periodontol (2000) 0.88

Regulation of human bone sialoprotein gene transcription by platelet-derived growth factor-BB. Gene (2009) 0.84

Radiolabelled biodegradable microspheres for lung imaging. Eur J Pharm Biopharm (2000) 0.84

Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect. Injury (2011) 0.82

IL-1 down-regulates platelet-derived growth factor-alpha receptor gene expression at the transcriptional level in human osteoblastic cells. J Immunol (1994) 0.81

Preparation and properties of macroporous brushite bone cements. Acta Biomater (2009) 0.79

Articles by these authors

Reliability of clinical guidelines in the detection of patients at risk following mild head injury: results of a prospective study. J Neurosurg (2004) 3.10

Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol (2006) 1.27

A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr (2007) 1.26

Cardiac function after CPAP therapy in patients with chronic heart failure and sleep apnea: a multicenter study. Sleep Med (2007) 1.06

Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J Pathol (2004) 0.97

Oestrogen receptor alpha and beta in female rat pituitary cells: an immunochemical study. Gen Comp Endocrinol (2007) 0.93

Local controlled release of VEGF and PDGF from a combined brushite-chitosan system enhances bone regeneration. J Control Release (2009) 0.92

Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. Lab Invest (2003) 0.89

Material-related effects of BMP-2 delivery systems on bone regeneration. Acta Biomater (2011) 0.88

Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol (2010) 0.87

In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. J Biomed Mater Res A (2012) 0.87

Isoquercitrin from Argemone platyceras inhibits carbachol and leukotriene D4-induced contraction in guinea-pig airways. Eur J Pharmacol (2005) 0.85

Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. Eur J Cancer (2007) 0.85

Validation of a method for non-invasive in vivo measurement of growth factor release from a local delivery system in bone. J Control Release (2006) 0.83

Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke (2004) 0.83

Cartilage repair by local delivery of transforming growth factor-β1 or bone morphogenetic protein-2 from a novel, segmented polyurethane/polylactic-co-glycolic bilayered scaffold. J Biomed Mater Res A (2013) 0.82

VEGF-controlled release within a bone defect from alginate/chitosan/PLA-H scaffolds. Eur J Pharm Biopharm (2009) 0.82

Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect. Injury (2011) 0.82

BMP-2, PDGF-BB, and bone marrow mesenchymal cells in a macroporous β-TCP scaffold for critical-size bone defect repair in rats. Biomed Mater (2015) 0.79

Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. Minim Invasive Ther Allied Technol (2008) 0.78

Endovascular repair of brachial artery transection associated with trauma. J Trauma (2004) 0.77

Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J Microencapsul (2013) 0.77

Characterization of estrogen receptors alpha and beta in uterine leiomyoma cells. Fertil Steril (2006) 0.76

Comparative analysis of the ERα/ERβ ratio and neurotensin and its high-affinity receptor in myometrium, uterine leiomyoma, atypical leiomyoma, and leiomyosarcoma. Int J Gynecol Pathol (2011) 0.76

Neurotensin and neurotensin receptor 1 expression in human myometrium and uterine leiomyomas. Biol Reprod (2010) 0.76

Differential expression of new splice variants of the neurotensin receptor 1 gene in human prostate cancer cell lines. Peptides (2009) 0.76

Smurf1 knocked-down, mesenchymal stem cells and BMP-2 in an electrospun system for bone regeneration. Biomacromolecules (2014) 0.76

[Inflammation and oxidative stress in respiratory and limb muscles of patients with severe sepsis]. Med Clin (Barc) (2012) 0.75

Development of PLGA-mannosamine nanoparticles as oral protein carriers. Biomacromolecules (2013) 0.75

Evaluation of the effectiveness of a bMSC and BMP-2 polymeric trilayer system in cartilage repair. Biomed Mater (2017) 0.75